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Abstract
Myoferlin (MYOF) is a mammalian ferlin protein with homology to ancestral Fer-1, a nematode protein that regulates
spermatic membrane fusion, which underlies the amoeboid-like movements of its sperm. Studies in muscle and endothelial
cells have reported on the role of myoferlin in membrane repair, endocytosis, myoblast fusion, and the proper expression of
various plasma membrane receptors. In this study, using an in vitro human breast cancer cell model, we demonstrate that
myoferlin is abundantly expressed in invasive breast tumor cells. Depletion of MYOF using lentiviral-driven shRNA
expression revealed that MDA-MB-231 cells reverted to an epithelial morphology, suggesting at least some features of
mesenchymal to epithelial transition (MET). These observations were confirmed by the down-regulation of some
mesenchymal cell markers (e.g., fibronectin and vimentin) and coordinate up-regulation of the E-cadherin epithelial marker.
Cell invasion assays using Boyden chambers showed that loss of MYOF led to a significant diminution in invasion through
Matrigel or type I collagen, while cell migration was unaffected. PCR array and screening of serum-free culture supernatants
from shRNA
MYOF transduced MDA-MB-231 cells indicated a significant reduction in the steady-state levels of several matrix
metalloproteinases. These data when considered in toto suggest a novel role of MYOF in breast tumor cell invasion and a
potential reversion to an epithelial phenotype upon loss of MYOF.
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Introduction
Breast cancer is the second leading cause of cancer mortality in
women [1], with the majority of the deaths due to metastatic
rather than localized disease [2]. Unrestrained cell division elicited
by somatic and/or germline mutations in several oncogenes and
tumor suppressor genes such as TP53 and Rb, and resistance to
programmed cell death are hallmarks of tumorigenesis [3,4]. For
tumor cells to efficiently metastasize, they often undergo a
pernicious transformation characterized by dramatically increased
migration and invasive capacity. Specifically, the spread of cancer
from a localized, self-contained tumor through tissue stroma and
into distant organs requires that cells achieve atypical, robust
motility and the capacity to aggressively degrade extracellular
matrix (ECM), enabling them to invade surrounding tissues and
vessels of the blood and lymphatic systems, and subsequently
establish nascent, secondary tumors [5,6].
The enhanced migration and invasive capacity of metastatic
tumor cells are the subject of intense investigation, and it is now
appreciated that several forms of cancer cell motility exist (i.e.,
single-cell, mesenchymal and amoeboid, protease-dependent,
protease-independent, and collective migration) [7,8]. Consider-
able progress has been made in identifying the potential molecular
components that mediate cell migration, and there is growing
evidence that intracellular vesicle trafficking of key proteins is
crucial for efficient migration [9]. In tumor cell migration, the
recycling of focal adhesion proteins (i.e., integrin receptor
recycling) through endocytosis/exocytosis is now thought to
contribute to the maintenance of polarized movement [10,11].
Moreover, endocytosis/exocytic trafficking has been implicated in
the delivery of proteolytic enzymes - including matrix metallopro-
teinases (MMPs) - to invadopodia, specialized protrusions utilized
by cells for degradation of ECM [12,13].
Ferlin proteins, an evolutionarily ancient family of large
integral membrane proteins [14], have been implicated in
vesicle trafficking in a variety of physiological settings. All
mammalian ferlins derive their names based on homology to
the C. elegans protein FER-1 (FERtilization defective-1). In
roundworms, fer-1 is required for the fusion of specialized
vesicles (membranous organelles) with the plasma membrane at
the leading edge of cell migration in spermatozoa; in the
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locomotion of sperm is impaired, and infertility results [15].
Human patients harboring FER1L1 (FER-1-like 1, dysferlin)
mutations manifest one of two autosomal recessive forms of
muscular dystrophy - limb girdle muscular dystrophy type 2B
and Myoshi myopathy [16], due to the inability of skeletal
muscle fiber sarcolemma to repair damaged muscle cells during
the normal course of biomechanical wear and tear [17–19].
Mutations in FER1L2 (otoferlin) result in non-syndromic
deafness (DFNB9), due to the failure of synaptic vesicles to
fuse and exocytose their cargo at the presynaptic plasma
membrane [20,21]. FER1L3 (myoferlin, MYOF), historically
considered to be a muscle-specific protein, has not yet been
directly associated with a distinct mammalian disorder, but
recent studies have indicated that its deletion results in impaired
mouse myoblast fusion into mature skeletal myotubes [22].
Furthermore, MYOF has been shown to mediate caveolae-
dependent endocytosis in human endothelial cells [23].
Recent reports indicate that MYOF is critically involved in the
function and/or stability of plasma membrane receptor tyrosine
kinases (RTKs). Bernatchez et al. demonstrated that ablation of
MYOF in vascular endothelial cells resulted in instability and
rapid degradation of the vascular endothelial growth factor
receptor 2 (VEGFR-2) [24]. Further research demonstrated that
the expression of another angiogenic tyrosine kinase receptor, Tie-
2, is also attenuated upon MYOF depletion in endothelial cells
[25]. Finally, Demonbreun et al. reported that knockout of MYOF
in mouse muscle resulted in diminished insulin-growth factor-1
receptor (IGFR) response and accumulation of the receptors in
vesicles targeted for degradation [26].
The studies reported above when considered in toto suggest
that MYOF may be a regulator of vesicle fusion events that
deliver essential cargos (e.g., growth factor receptors, cell
adhesion molecules, and other cell-surface proteins) to and/or
from the plasma membrane. Inasmuch as tumor cell metastatic
dissemination involves the convergence of receptors, signal
transduction pathways, adhesion and matrix proteolytic mole-
cules at the leading edge of a tumor cell, we proposed that
MYOF (and perhaps other ferlin proteins) may be involved in
one or more steps in tumor progression and/or spread.
Microarray and proteomic studies in the cancer literature have
reported MYOF expression in breast cancer specimens and
relevant cell lines [27–29]. For example, in one microarray
study, MYOF was 1 of 39 genes found to be over-represented
in breast carcinoma [28]. These observations prompted us to
hypothesize that MYOF may be an important protein in breast
cancer cells for their mobilization during cellular migration
and/or invasion.
We recently reported on the mathematical modeling of the
role of MYOF in breast cancer cell invasion [30]. In the
current manuscript, we present novel data confirming the
computational modeling and show, in addition, that MYOF-
deficient MDA-MB-231 human breast cancer cells exhibit a
more epithelial shape compared to the mesenchymal morphol-
ogy of wild-type MDA-MB-231 cells, suggesting that some
features of a mesenchymal-to-epithelial transition (MET) phe-
notype [31] may exist in the absence of functional MYOF
protein. Matrigel and collagen I based invasion assays demon-
strated that depletion of MYOF diminished the invasive ability
of cancer cells. In congruence with the mathematical modeling
results, we report that the decreased invasive capacity is due, at
least in part, to the down-regulation of MMP expression in
MYOF-deficient cells.
Results
Myoferlin in Breast Cancer Cells Correlates with Cell
Invasiveness
To correlate the expression of MYOF with the invasive capacity
of breast cancer cells, we analyzed five mammary cell lines: MCF-
10A, MCF-7, T47D, BT549, and MBA-MB-231. The MCF-10A
line was chosen as a model for non-cancerous, non-invasive
mammary epithelial [32]. MCF-7 and T47D cells model non2/
low-invasive breast cancers, while BT549 and MDA-MB-231 have
high invasive capacity [33].
Examination of MYOF mRNA expression in each of the cell
lines indicated that MYOF expression was 2.44-fold higher in the
invasive lines (BT549 and MDA-MB-231) relative to non2/low-
invasive cells (MCF-10A, MCF-7, and T47D) (Figure 1A and B).
In congruence, higher MYOF protein expression was observed by
immunoblotting in the highly-invasive breast cancer cell lines
relative to those with low invasive potential (Figure 1C). To
expand upon this, we examined the transcriptional profiling data
available on 51 established breast cancer lines generated by Neve
and colleagues (http://cancer.lbl.gov/breastcancer/data) [34].
Those 14 cell lines which clustered into the invasive, basal B-like
subset exhibited statistically significantly greater MYOF expression
compared to the 25 cell lines of the luminal phenotype as
determined by two MYOF probesets (201798_s_at and
211864_s_at, Figure S1).
Building on these observations, we mined published microarray
data available through the ArrayExpress database (www.ebi.ac.
uk/arrayexpress) [35]. Our query returned microarray data
(accession: E-TABM-276) from Cheng et al. [36] consisting of a
panel of 23 microdissected primary invasive ductal carcinoma
tissues, 28 adjacent stromal tissues, and 10 healthy controls. When
MYOF expression was categorized by disease state, we observed
significantly higher MYOF mRNA expression in tissues from
patients with invasive ductal carcinoma compared with samples
from healthy individuals (Figure S2). Collectively, these data
suggest a potential correlation between MYOF over-expression
and invasive breast carcinoma.
Myoferlin Knockdown Promotes a Mesenchymal to
Epithelial Change
Given a possible association between MYOF expression and
invasive potential, we examined whether MYOF contributed to
breast cancer cell invasion. We selected the MDA-MB-231 cells
for these experiments since they exhibited high levels of MYOF
protein expression in our survey, and were previously shown to
have the greatest invasive capacity compared to a large panel of
breast cancer cell lines [34]. Stable lines of MYOF-deficient
MDA-MB-231 cells (231
MYOF-KD) were generated using lentivi-
rus-based delivery of short hairpin ribonucleic acids (shRNAs)
targeting human MYOF (Figure S3). Control cell lines (231
LTV-ctrl)
were generated in parallel using a non-human gene targeting
construct. Selective knockdown of MYOF protein expression was
confirmed by immunoblotting (Figure 1D). Of the three constructs
initially screened (#10628, 10630, and 1522), #10628 yielded the
most efficient knockdown (mean 94% compared with controls,
n=4) and was used in subsequent experiments.
An unexpected, but interesting shape change appeared in the
231
MYOF-KD cells, wherein they exhibited a more epithelial-like
(cobblestone) morphology which diverged from the fibroblastic,
spindle shape of the wild type and 231
LTV-ctrl cells (Figures 2 and
3). The 231
MYOF-KD morphology was stable, and was maintained
after 10 continual passages in culture (data not shown). By
immunofluorescent microscopy, we noted that 231
MYOF-KD cells
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in greater detail using atomic force and scanning electron
microscopy, the morphological divergence between 231
MYOF-KD
and control cells was very prominent (Figure 3). At the cellular
level, 231
LTV-ctrl cells often appeared elongated with tapering
cytoplasmic poles, having one or more small lamellipodia and
relatively short filopodia, and actin filaments oriented along the
long axis of the cell (Figure 3). In contrast, 231
MYOF-KD cells
exhibited a flattened, polygonal shape with broad lamellipodia,
and elongated filopodia that tended to orient toward neighboring
cells. Collectively, these results suggested a potential reversion of
epithelial-mesenchymal transition, i.e., mesenchymal-epithelial
transition (MET), at the morphology level.
The MET-like morphological changes prompted us to examine
whether the expression of common epithelial-mesenchymal
transition (EMT) markers (e.g. vimentin, fibronection, N-cadherin,
and E-cadherin) was affected by MYOF depletion. By immuno-
blotting, 231
MYOF-KD cells expressed higher levels of the epithelial
marked E-cadherin, and lower levels of mesenchymal markers,
fibronectin and vimentin, than 231
LTV-ctrl cells (Figure 4). MDA-
MB-231 cells do not natively express N-cadherin, so it was not
surprising that N-cadherin was undetectable in 231
LTV-ctrl and
231
MYOF-KD cells (data not shown). The results of this screen of
EMT markers suggest that the morphologic shift associated with
MYOF-depletion may be correlated with MET changes at the
molecular level. In a survey using a qRT-PCR-based array of
Figure 1. Myoferlin expression in breast cancer. (A) Quantitative RT-PCR results of MYOF mRNA levels in a panel of breast cancer cell lines,
normalized to 18 S and compared to the nonmalignant breast epithelial cell line MCF-10A (mean 6 s.d., n=3 per cell type). No statistical significance
was detected in comparing pairs of cell lines (Kruskal-Wallis with Dunn’s multiple comparison test). (B) Representation of the data in subpanel A
grouped by known invasive capacity of the cells (2 tailed, p=0.003, Mann Whitney). (C) Immunoblotting for MYOF in breast cancer cell lines.
Densitometry measurements was done by normalizing the density of MYOF to respective GAPDH or actin staining, and further normalized to the
nonmalignant mammary epithelial cell line MCF-10A (n=4, no statistical significance detected by Kruskal-Wallis with Dunn’s multiple comparison
test). An immunoblot image is shown in the subpanel. (D) Myoferlin knockdown in breast cancer cells. Immunoblot showing the expression of MYOF
in MDA-MB-231 wild type (WT), lentiviral transduction control (LTV-ctrl), and MYOF knockdown cell lysates using three Sigma-Aldrich MISSIONH
shRNA constructs (#1522, 10628, and 10630).
doi:10.1371/journal.pone.0039766.g001
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correlate with the Western results in that fibronection mRNA was
down-regulated 3.46-fold while that of E-cadherin was up-
regulated 2.58-fold in 231
MYOF-KD cells compared with controls,
although no significant change was found for vimentin (Table S1).
Myoferlin Depletion Does Not Alter Cell Proliferation or
Cell Cycle Distribution
We next subjected 231
LTV-ctrl and 231
MYOF-KD cells to
proliferation assays. First, to assess general proliferative status,
MTS assays were conducted on wild-type, 231
LTV-ctrl, and
231
MYOF-KD cells. We observed no change in the growth rates
of the three cell types (Figure S4A), indicating that MYOF does
not profoundly alter tumor cell growth. To verify this result, we
then carried out cell cycle analysis on the three cell types. Again,
we detected no change in cell cycle activity in MYOF-depleted
cells compared to wild-type or 231
LTV-ctrl cells (Figure S4B).
Myoferlin Depletion Attenuates Cell Invasiveness
MYOF deficiency was not associated with a change in
chemotaxis (Figure 5A) in Boyden chamber assays when 10%
fetal bovine serum was used as the chemoattractant. However,
231
MYOF-KD cells exhibited a significant ,38% reduction in
invasiveness into Matrigel relative to 231
LTV-ctrl cells (Figure 5B).
These results suggest that targeted disruption of MYOF expression
selectively attenuates invasiveness through reconstituted basement
membrane matrix, with little effect on chemotactic migration.
Myoferlin Depletion Alters MMP Expression
The reduced invasive capacity of 231
MYOF-KD cells led us to
study whether proteins associated with tumor-microenvironment
interactions may be altered following MYOF depletion. Specifi-
cally, given that MYOF has been implicated in exocytosis [37], we
hypothesized that its depletion might decrease the secretion of
matrix metalloproteinases (MMPs) and/or tissue inhibitors of
MMPs (TIMPs), as these are vital endopeptidases for degrading
Figure 2. Morphology change following myoferlin depletion in MDA-MB-231 cells. Immunofluorescence micrographs showing the
morphology of MDA-MB-231 wild type (WT), lentiviral transduction control (LTV-ctrl), and myoferlin knockdown (MYOF-KD) stable cell lines in culture.
Note the more epithelial morphology of MYOF-KD cells compared to the more mesenchymal appearance of the WT and LTV-ctrl cells. Bar=50 mm.
doi:10.1371/journal.pone.0039766.g002
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conditioned, serum-free supernatants from 231
LTV-ctrl and
231
MYOF-KD cells and performed an array-based multiplex
sandwich ELISA to screen the expression of several of these
endopeptidases and their regulators (Figure S5). We observed a
reduction in the secretion of MMP-1, -2, -3, and -8 from 231
MYOF-
KD cells (MMP-2, -3, and -8 were undetectable in 231
MYOF-KD
cells). MMP-13 levels were not drastically affected, while in
contrast, levels of MMP-9 and -10 were elevated in 231
MYOF-KD
cells. In addition, the 231
MYOF-KD cells had reduced levels of
TIMP-4, but no notable changes in TIMP-1 and -2 releases were
evident. Of the detectable MMPs, the most pronounced change
was the decrease in secreted MMP1. However, given the small
sample size of this screening experiment (n=1), statistical analysis
could not be performed to validate the significance of the observed
fold changes. Therefore, to validate the change in MMP1,
multiple biological replicates of concentrated 24 hour supernatant
from 231
LTV-ctrl and 231
MYOF-KD cells were subjected to
immunoblotting (Figure 6A), and secreted MMP1 was verified to
be decreased in 231
MYOF-KD cells compared to controls. We also
confirmed the diminution (,97%) of pro-MMP1 secretion into the
extracellular milieu by solution-phase ELISA of 231
LTV-ctrl and
231
MYOF-KD cells (Figure 6B). To confirm the functional
association between MYOF knockdown and MMP1 depletion,
we investigated the invasive capacity of 231
MYOF-KD cells through
a collagen I matrix, since fibrillar collagen is a key substrate for the
MMP1 enzyme [39] and Matrigel lacks collagen I [40]. In support
of these previous observations, 231
MYOF-KD cells exhibited a
,62% reduction in invasion through collagen I matrix compared
with 231
LTV-ctrl cells (Figure 6C).
We next tested whether MMP1 expression was diminished at
the transcriptional level using qRT-PCR. Surprisingly, MMP1
mRNA levels were reduced over an average 18.8-fold in 231
MYOF-
KD cells when compared with the 231
LTV-ctrl cells (Figure S6). This
finding of MMP1 mRNA down-regulation in 231
MYOF-KD cells
was striking, as there have been no reports from other laboratories
suggesting that MYOF may contribute to gene expression
regulation. Since the diminution of MYOF in the MDA-MB-
231 cells was mediated by shRNA (which mimics the function of
microRNA molecules [41]), we recognized the potential that
Figure 3. Morphology change following myoferlin depletion in MDA-MB-231 cells. Atomic force and scanning electron microscopy images
showing the spindle, elongated shape of lentiviral control (LTV-ctrl) cells and the more flat and circular morphology of myoferlin depleted (MYOF-KD)
cells. AFM imaging shows pronounced actin stress fibers (black arrows) oriented along the long axis being evident in the control but not in the MYOF
depleted cells. Cytoplasmic poles, lamellipodia and filopodia are observable in the SEM images. White arrowheads indicate the leading edge of cells.
doi:10.1371/journal.pone.0039766.g003
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the RNAi targeting construct. We therefore screened additional
MYOF-targeting shRNA constructs. Although two constructs
(Figure S3) yielding partial MYOF knockdown (mean 64–66%
knockdown compared with controls, n=4) were not associated
with reductions in MMP1 (data not shown), an additional
construct (#320398) that targets the coding sequence of MYOF
(Figure S3) resulted in a mean of 91% MYOF knockdown (n=3)
and was also associated with significant reductions in MMP1
release (Figure S7A and B).
In addition, we performed an extensive in silico analysis to
examine potential off-target effects of construct #10628. A search
through the human nucleotide database for sequences similarity to
the 21 nucleotide sequence of #10628 did not reveal MMP1 as a
transcript with significant alignment (BLASTN version 2.2.24+)
[42]. A search through the microRNA database TargetScan
Custom (http://www.targetscan.org/, release 5.1, accessed Octo-
ber 10, 2010) using the 2–8 mer sequence of ‘‘CTCTACT’’ from
the #10628 construct did not show MMP1 to be a potential
target. Construct #10628 is from a clone cataloged by the RNAi
Consortium (http://www.broadinstitute.org), and a search
through the consortium database did not show the MYOF
shRNA construct as a non-targeting clone with matching
transcripts in the MMP1 gene. Finally, the construct sequence
was placed into the miRBase [43] to search against known
miRNAs. There were no matches of the sequence against mature
miRNAs, and all matches to stem-loop sequences using the
SSEARCH method were from non-human species (silk worm,
mosquito, and platypus) and were not significant (E-value
..0.01).
We did additional PCR screening using a commercial
extracellular matrix and adhesion molecules array to profile the
expression of MMP genes (Table S2). The screen validated the
MMP1 PCR results showing down-regulation of MMP1 mRNA in
231
MYOF-KD cells. Specifically, of the four MMPs (MMP1, 10, 11,
14) expressed at reasonable levels in the MDA-MB-231 cells (i.e.
Figure 4. Expression of EMT markers following myoferlin depletion in MDA-MB-231 cells. (A) Representative immunoblots (n=3) of
select EMT markers in lentiviral control (LTV-ctrl) and myoferlin depleted (MYOF-KD) cells serum-starved for 24 h. (B) Graphs illustrating the semi-
quantitative evaluation of the expression of EMT markers by densitometry analysis of blots (n=3). Density was presented in the graph as ‘‘relative
density (%)’’ with density of lentiviral controls normalized to 100%, and statistical testing was done with the 1-sample t-test.
doi:10.1371/journal.pone.0039766.g004
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regulated ($ 62 fold-change) at the transcription level by MYOF-
depletion.
Discussion
We provide in silico and experimental evidence that MYOF
plays a critical and previously unrecognized role in breast tumor
cell invasion. Mining of transcriptome and proteome databases
from breast cancer cell lines revealed higher levels of MYOF
mRNA and protein in the more invasive lines compared with
poorly invasive breast tumor cells or normal mammary epithelial
cells (i.e., MCF-10A). Published microarray datasets using breast
cancer cell lines [34] also support greater MYOF expression in the
invasive basal B group compared with the luminal subtype. In a
separate study, MYOF was found to be 1 of 39 genes selectively
over-expressed in breast carcinoma using 20 human breast cancer
cases [28]. These data suggested to us that MYOF is a potentially
important protein in breast cancer biology.
The premise that MYOF contributes to cancer invasion was
based on several reports implicating a role for ferlin proteins in
intracellular vesicle trafficking, including cell motility. For
example, Ward and colleagues demonstrated that temperature-
sensitive mutations in the ancestral fer-1 gene in C. elegans led to
fertility impairments yielding immotile spermatozoa secondary to
defects in vesicle recycling at the leading edge of the cell [15,44].
Mechanistically, mutations in C2 domains of fer-1 altered calcium
sensitivity and subsequently impeded calcium-dependent fusion of
intracellular vesicles to the plasma membrane that drives the
amoeboid movement of the roundworm sperm cells [15]. Vesicle
trafficking has been implicated in several important steps during
cell motility [9]. Based on these observations, coupled with the
observation that MYOF expression was increased in breast cancer
specimens and breast cancer cell lines with high invasive potential,
we hypothesized that MYOF depletion would impair the motility
of breast cancer cells. And this appeared to be the case. End-point
Boyden chamber assays accessing cell motility initially detected no
overall change in migration during a 24 hour assay period. This
was somewhat surprising in light of the work of Achanzar et al.
[45] demonstrating that mutation of fer-1 resulted in profound
defects in amoeboid migration of C. elegans sperm cells. However,
recent work from our lab using live-cell imaging clearly shows that
MYOF depletion leads to fundamental changes in the mode of
breast tumor cell motility (Volakis et al., in preparation, J
Biomechanics), suggesting that MYOF loss also contributes to
disturbances in cell migration on two-dimensional surfaces (work
in progress).
Tumor cell invasion into distant tissues to establish secondary
malignancies is a hallmark of cancer metastasis and cancer-related
death [4]. In many cases, enhanced tumor cell migration as well as
local and distant invasion are preceded by an EMT that converts
sessile epithelial cells into actively migratory and invasive cells
[46,47]. In order for efficient migration and invasion to occur, in
many instances cancer cells must secrete several MMPs for
basement membrane and stromal ECM degradation [48]. We
probed the invasive capacity of breast tumor cells (MDA-MB-231)
following shRNA directed depletion of MYOF (shRNA
MYOF), and
noted a profound deficit in the ability of cells to invade through
Matrigel (basement membrane mimic) [49] and collagen type I
(stromal ECM mimic) [50]. These observations indicated that
MYOF disruption may perturb one or more MMPs that are
essential for effective cell invasion through the ECM or collagen I
[48]. Indeed, screens of several MMPs using qRT-PCR and
protein immunoassay arrays suggested that MMPs-1, 3, 8, 12, 13,
14, and 16 were down-regulated in MDA-MB-231 cells in which
MYOF was knocked down by RNAi (Figure S5 and Table S2).
Interestingly, MMP-9 appeared to be up-regulated under these
same conditions, indicating the MYOF depletion results in
selective changes in MMPs.
To evaluate the effect of abolishing MYOF on MMP
expression, we probed MMP-1 further, because our data revealed
a nearly complete loss of MMP-1 when shRNA
MYOF was
expressed in MDA-MB-231 cells. Quantitative RT-PCR and
Western blotting showed essentially no detectable MMP-1 mRNA
or protein in 231
MYOF-KD cells. Moreover, we detected virtually
no pro-MMP-1 reactive protein by ELISA. Thus, it appears that
MYOF may play a role in MMP gene expression in addition to
other mechanisms it may influence, such as MMP secretion via
vesicle trafficking. We are currently exploring the mechanistic
basis for this apparent alteration in MMP gene expression in
human breast tumor cells.
To authenticate that our shRNA results were not due to off-
target effects on the MMP mRNAs, we conducted an extensive in
silico analysis using several software packages available in the
Figure 5. Myoferlin depletion reduces invasive but not migratory capacity of MDA-MB-231s control (LTV-ctrl) and MYOF depleted
cells (MYOF-KD). (A) Boyden chamber migration assay of MDA-MB-231 cells moving across 8 mm porous membranes towards a 10% serum
gradient for 24 h (mean 6 s.d., n=3, unpaired 2-tailed t-test). (B) 24 h Boyden chamber invasion results of MDA-MB-231 cells across a 100% Matrigel
coated 8 mm porous membrane towards a 10% serum chemoattractant (mean 6 s.d., n=3, unpaired 2-tailed t-test).
doi:10.1371/journal.pone.0039766.g005
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MYOF
constructs predicted the targeting of any nucleic acid sequences
within the human MMP-1 gene. In addition, we found MMP1
expression to be also down-regulated when MYOF expression
was knocked down using an alternative shRNA construct with
similar knock down efficiency.
Another unanticipated finding in the current studies was the
partial reversion of the mesenchymal-like shape in wild-type and
control MDA-MB-231 cells to a more epithelial-like phenotype in
231
MYOF-KD cells. We verified this potential MET event using
immunofluorescence, scanning, and atomic force microscopy. In
addition, we also demonstrated the likelihood of an MET in the
setting of depleted MYOF using immunoblotting that revealed
down-regulation of fibronectin and vimentin and up-regulation of
E-cadherin.
In a recent paper from our group, MYOF depletion was shown
to lead to the down-regulation of the phosphorylation of several
receptor tyrosine kinases, including EphB4, FGFR2, Hck, IGF-IR,
JAK2, TXK, VEGFR2 [30]. This observation is in agreement
with the work of Demonbreun et al. demonstrating that loss of
MYOF led to impaired insulin-like growth factor I receptor (IGF-
IR) signaling in a murine model [51]. In separate reports, MYOF
was shown to be required for Tie-2 (angiopoietin-1 receptor)
activation [25] and vascular endothelial growth factor receptor 2
(VEGFR-2) expression in vascular endothelial cells [24]. More-
over, Sharma et al., showed that disruption of dysferlin, a close
molecular cousin of MYOF, in endothelial cells led to poly-
ubiquitination and proteasomal degradation of platelet endothelial
cellular adhesion molecule-1 (PECAM-1/CD31) signaling [52].
These data, when considered collectively and in the context of
our breast tumor cell investigations, implicate MYOF as a critical
participant in key processes within the intracellular vesicle
trafficking mechanism including cell motility, MMP expression/
secretion, and RTK activation. Our work is the first examination
of the role of MYOF in cancer cell biology and may shed light on
essential features of vesicle shuttling of important cargos within
tumor cells that participate in cancer progression and metastasis.
Materials and Methods
Cell Culture Methods and Cell Line Authentication
Human MCF-10A (generously provided by Dr. Joan Brugge,
Boston, MA, [32,53]), MCF-7 (HTB-22, ATCC, Bethesda, MD),
MDA-MB-231 (HTB-26, ATCC), T47D (HTB-133, ATCC), and
BT549 (generous gift from Dr. Lisa Yee, Columbus, OH; HTB-
122, ATCC) cells were used in this study. MCF-10A cells were
maintained in Dulbecco’s Modified Eagle Medium Ham’s F12
(DMEM/F12, Gibco, Carlsbad, CA) supplemented with 5% horse
serum (Gibco), 20 ng/ml hEGF (PeproTech, Rocky Hill, NJ),
0.5 mg/ml hydrocortisone (Sigma-Aldrich, St. Louis, MO),
100 ng/ml cholera toxin (Sigma-Aldrich), 10 mg/ml bovine insulin
(Sigma-Aldrich), and 1% penicillin/streptomycin (Gibco). MCF-7
and MDA-MB-231 cells were maintained in DMEM with 4.5 g/L
D-glucose supplemented with 10% fetal bovine serum (FBS,
Gibco). T47D and BT549 cells were cultured in RPMI-1640 with
10% FBS.
The cell lines used in this study were authenticated by DNA
profiling using short tandem repeat (STR) analysis on a
PowerPlex 1.2 System (Promega, Madison, WI) at John Hopkins
University (Fragment Analysis Facility, Baltimore, MD). Fur-
Figure 6. Myoferlin depletion attenuates MMP1 expression
and collagen I invasion capacity of MDA-MB-231 cells. (A)
Representative (n=3) immunoblotting results of secreted MMP1 in 24 h
serum starved supernatant of MDA-MB-231 lentiviral control (LTV-ctrl)
and myoferlin knockdown (MYOF-KD) cells. Recombinant human matrix
metalloproteinase-1 was used as a standard. Verification of myoferlin
knockdown was done in the corresponding cell lysates with GAPDH as a
loading control. (B) Secreted pro-MMP1 was evaluated in 231
LTV-ctrl and
231
MYOF-KD cells (n=2) using ELISA (mean 6 s.d., Kruskal-Wallis test/
Dunn’s multiple comparison analysis). (C) Results from Boyden chamber
invasion assays using a coating of 3 mg/ml of rat tail collagen I to
evaluate the invasive capacity of 231
LTV-ctrl and 231
MYOF-KD cells (n=3,
mean 6 s.d., Kruskal-Wallis test/Dunn’s multiple comparison analysis).
doi:10.1371/journal.pone.0039766.g006
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the morphology changes seen in MDA-MB-231 myoferlin-
deficient cells (231
MYOF-KD), the identity of the 231
MYOF-KD
cells as MDA-MB-231s was also authenticated through short
tandem repeat profiling.
Lentiviral shRNA Transduction
Recombinant lentiviral particles containing non-target control
shRNA and human myoferlin targeted shRNA
(TRCN0000010628, TRCN0000010630, TRCN0000001522,
and TRCN0000320398, Figure S3) in the pLKO.1 vector were
purchased from Sigma-Aldrich (MISSIONH). The myoferlin
constructs are referred to as #10628, #10630, #1522 and
#320398, respectively, in the body of the manuscript. For
lentiviral transduction, cells were seeded in 24-well culture plates
and incubated overnight at 37uCi n5 %C O 2 in a humidified
atmosphere. Media was replaced with media containing 8 mg/ml
hexadimethrine bromide (Sigma-Aldrich) and lentiviral particles
were added to subconfluent at a multiplicity of infection (MOI) of
at least 1. After overnight incubation (37uC, 5% CO2), virus-
containing supernatant was replaced with complete media and
incubated overnight. Transduced cells were selected in media
containing an appropriate puromycin concentration as predeter-
mined by a puromycin kill curve.
RNA Extraction and Quantitative Real Time-Polymerase
Chain Reaction (qRT-PCR)
Total RNA was extracted using TRIzolH reagent (Invitrogen,
Carlsbad, CA) according to the manufacturer’s protocol up to the
chloroform extraction and centrifugation step. The resulting
aqueous phase was mixed with an equal volume of 70% ethanol
and applied to an RNeasy mini column (QIAGEN, Valencia, CA)
and processed according to the manufacturer’s protocol with on
column DNAse digestion. Total RNA was quantified by UV
absorbance at 260 nm and 280 nm on a NanoDrop 2000
(Thermo Scientific, Waltham, MA), and 1–2 mg total RNA from
each sample were reverse-transcribed to cDNA using oligo-dT18
and random hexamer primers with a Transcriptor First Strand
cDNA Synthesis Kit (Roche Applied Science, Indianapolis, IN).
Quantitative RT-PCR was performed using an equal amount of
cDNA per sample on a LightCyclerH 480 II System (Roche
Applied Science) using primer-probe sets specific to MYOF,
MMP1, RLPO and 18 S rRNA (Applied Biosystems, Carlsbad,
CA) with the LightCyclerH 480 Probes Master Mix, and results
analyzed with the LightCyclerH 480 Software.
Immunofluorescence
MDA-MB-231 cells cultured on glass coverslips and serum-
starved for 24 h were fixed for 1 h in 4% (w/v) paraformalde-
hyde/PBS, permeabilized for 15 min with 0.2% (v/v) Triton X–
100/PBS, and blocked for 1 h in 5% normal goat serum/1%
nonfat dry milk/PBS. Samples were incubated with antibodies
directed against myoferlin (1:400, Sigma) overnight at 4uC. After
washing, cells were exposed to fluorochrome-conjugated second-
ary antibodies (Molecular Probes). After further stringent washing
in PBS, actin cytoskeleton was stained with AlexaFluor 488-
phalloidin (Molecular Probes) for 20 min. Nuclei were stained and
cells mounted with ProLongH Gold Antifade Reagent with DAPI
(Invitrogen) and visualized with confocal laser scanning microsco-
py (Olympus FV 1000 Spectral Confocal system; Olympus
America Inc., Center Valley, PA).
Atomic Force (AFM) and Scanning Electron Microscopy
(SEM)
MDA-MB-231 lentiviral control and myoferlin-deficient cells
were seeded in 60 mm cell culture dishes (5–8610
5 cells), and
allowed to grow to 80–90% confluence for AFM analysis. Prior to
AFM analysis, culture media was exchanged for CO2 independent
media (Invitrogen) supplemented with 1% FBS, 1% Penicillin/
Streptomycin and 4 mM L-Glutamine, for optimal cell survival
during the atomic force measurements. A Bioscope II instrument
(Veeco, Plainview, NY) mounted on the stage of an Axiovert 200
inverted optical microscope (Zeiss, Oberkochen, Germany) was
used in contact mode for live cell imaging. Silicon nitride (SiN)
triangular cantilevers (Veeco) 200 mM in length with a tip angel
h=35u and a nominal spring constant k of 0.01 N/m were used to
image the cells. Image acquisition was done at a scanning rate of
0.5 Hz with 5126512 lines resolution for recording the height and
the deflection channels. All images were recorded with a scan size
area of 70–80 mm
2 covering ,5 cells, with 4–5 areas completed
per cell type. The experiments were repeated three times and the
data were analyzed using version 7.30 of the NanoScope software
(Veeco).
For SEM, cells cultured on thermoplastic coverslips (Therma-
nox
TM, Nunc, Waltham, MA) were fixed with 3% glutaraldehyde,
post-fixed with 1% OsO4 and dehydrated through an ethanol and
hexamethyldisilazane series. Samples were mounted onto SEM
studs and prepared for SEM using a Pelco Model 3 sputter coater
with gold-palladium (0.07 mbar, 17 mA, 110 s) and imaged with
an FEI Nova NanoSEM microscope (FEI Company, Hillsboro,
OR).
Protein Extraction and Immunoblotting
Cells were rinsed with PBS and lysed for 30 min in cold RIPA
lysis buffer supplemented with protease inhibitor cocktail (Sigma-
Aldrich) and 1 mg/ml of pepstatin A (USB, Santa Clara, CA). Cell
lysates were centrifuged for 10 min at 17,0006g and 4uC.
Supernatant aliquots were assayed for protein concentration using
the BCA Protein Assay (Pierce, Rockford, IL) with bovine serum
albumin as a standard. Total protein from each lysate (30 mg per
lane) were resolved by SDS-PAGE and transferred to nitrocellu-
lose membranes. Non-specific binding was blocked by incubation
in Tris-buffered saline (pH 8) containing 0.1% Tween-20 and 5%
non-fat dry milk. Membranes were probed with primary
antibodies against: b-actin (Santa Cruz Biotechnology, Santa
Cruz, CA), GAPDH (Chemicon, Billerica, MA), myoferlin (Sigma-
Aldrich), E-cadherin (EP700Y, Abcam, Cambridge, MA), vimen-
tin (Sigma-Aldrich V6630), or MMP1 (R&D Systems, Minneap-
olis, MN) diluted in blocking solution. After washing, membranes
were exposed to horseradish peroxidase-conjugated secondary
antibodies and immune complexes were revealed with Super-
Signal West Femto chemiluminescent substrate (Pierce), visualized
using the VersaDoc Imaging System and analyzed with Quantity
One analysis software (Bio-Rad, Hercules, CA).
Supernatant Collection and Immunoblotting
Cell conditioned media were collected after the cells were plated
at equal densities in 100 mm dishes, then serum starved in 4 ml of
basal media for 24 h. The conditioned media were concentrated
50-fold with Amicon Ultra-4 10-kDa centrifugal filters (Millipore,
Billerica, MA), and equal volumes of concentrated media were
reconstituted in sample buffer and resolved by SDS-PAGE.
Human recombinant MMP1 (rhMMP-1) from conditioned media
of rhMMP-1 expressing NS0 mouse myeloma cells (WBC024;
R&D Systems) was used as a positive control. Gels were processed
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using anti-human mouse monoclonal antibodies against MMP-1
(MAB901; R&D Systems) and fibronectin (610077; BD Trans-
duction Laboratories, San Jose, CA).
MMP Expression Array and MMP1 ELISA
ECM proteins (MMP1, -2, -3, -8, -9, -10, and -13 and TIMP1, -




MYOF-KD cells were determined by an antibody array
(RayBioH human matrix metalloproteinase antibody array 1,
RayBiotech, Inc., Norcross, GA) following the manufacturer’s
protocol. Each array membranes contained duplicates for each
ECM protein along with positive and negative controls. The blots
were imaged and quantified by densitometry (Quantity One
software, Bio-Rad), and values normalized to total protein of the
corresponding cell lysates.
Secreted pro-MMP-1 in cultured media of cells was detected by
quantitative ELISA (DMP100; R&D Systems). Conditioned
cultured media were collected by plating equal densities of each
cell type in 100 mm culture dishes followed by serum-starvation
for 24 h. Unconcentrated, conditioned media samples were run in
duplicate in the ELISA and processed according to manufacturer’s
instructions. Colorimetric results were read at 450 nm with a
wavelength correction of 570 nm in a MRX Microplate Reader
(Dynex Technologies, Chantilly, VA). MMP-1 concentrations
were determined by interpolation using human recombinant pro-
MMP-1 as a standard. In cases where the secreted pro-MMP1 was
undetectable, it was assigned the assay’s lowest limit of detection
(0.021 ng/ml).
MTS Proliferation Assay and Cell Cycle Analysis
Cells were plated in 96-well plates at a density of 2500 and/or
5000 cells per well and assayed at 24, 48, and 72 h after plating
using the CellTiter 96 AQueous Non-Radioactive Cell Prolifer-
ation Assay (Promega), according to the manufacturer’s instruc-
tions.
For flow cytometric analysis of MYOF depleted breast cancer
cells, cells were fixed in 70% ethanol and stained in PBS containing
0.1% Triton X-100, 200 mg/mL of RNase, and 50 mg/mL
propidium iodide (Sigma-Aldrich). DNA content was measured on
a FACS Calibur or LSRII flow cytometer (Becton-Dickinson)), and
data were acquired and analyzed using flow cytometer software
(BD). Each analyzed sample contained at least 1610
6 cells.
Migration and Invasion Assays
Cells were washed with PBS, trypsinized, pelleted and
resuspended in serum-free DMEM. Cells were then seeded onto
Boyden Chamber inserts (8 mm pores; Millipore) at a density of
7.5610
4 cells in 24-well plates with 10% FBS containing DMEM
in the bottom chamber as a chemo-attractant. In parallel, input
controls were seeded with the same number of cells in the same
volumes of serum-free and 10% FBS media without inserts. Cells
were incubated (37uC, 5% CO2) for 24 hours. The inserts were
processed by rinsing in PBS and fixation with 3.7% formaldehyde
containing 0.05% crystal violet for 10 min. After repeated washes
with PBS and distilled water the chambers were air-dried.
Migrated cells on the bottom of the inserts were collected with
cotton swabs and placed into Eppendorf tubes. Crystal violet dye
was extracted from the Q-tips and input control wells with 80%
methanol for 30 min, and quantified at 570 nm. Percentage
migration was calculated using the ratio of the migrated cells over
the total cells (input control) to determine the percentage of cell
migration. For invasion, the Boyden Chamber assay was
conducted in the same manner but with the addition of 20 mlo f
growth factor reduced Matrigel (BD) or 3 mg/ml collagen I (rat
tail, Gibco) to the top of the insert and allowed to gel for 1 h at
37uC, 5% CO2.
Quantitative Reverse Transcription PCR Array
RT2 Profiler
TM PCR array (SABiosciences, Frederick, MD) was
performed for EMT-associated genes (cat #PAHS-090) and
human extracellular matrix and adhesion molecules (cat #
PAHS-013) following manufacturer’s protocol. Briefly, total
RNA was extracted as described in the qRT-PCR section from
lentiviral control and myoferlin-deficient MDA-MB-231 cells that
had been in culture for 10 consecutive passages. Complementary
DNA was generated from 1 mg of total RNA per cell type using
random hexamers and oligo-dT18 primers as part of the RT2 First
Strand Kit (SABiosciences). Equal amounts of dilute cDNA was
mixed with LightCyclerH 480 SYBR Green I Master mix (Roche)
and aliquoted to each well of the PCR array plate containing pre-
filled gene-specific primer sets, and PCR was performed according
to manufacturer’s instructions for the Roche LightCyclerH 480.
The LightCyclerH 480 Software (Roche Applied Science) was used
to calculate the threshold cycle (crossing point, Cp) values for all
the transcripts in the array. The Cp values were exported into a
spreadsheet-based PCR array data analysis template (SABios-
ciences) to calculate fold changes in gene expression using the
DDCt method.
Statistical Analysis
Graphical representation and statistical analysis of data were
done using Prism version 5 (GraphPad). Error bars represent
standard deviation in all cases, unless differently noted. Statistical
significance was determined by appropriate statistical tests
following normality testing of the data, using the KS, D’Agostino
& Pearson omnibus and/or Shapiro-Wilk normality tests. Com-
parisons between 2 groups with Gaussian distribution were carried
out with the 2-tailed student t-test for unpaired samples, while
those among 3 or more groups were carried out with one-way
ANOVA followed by Tukey’s Multiple Comparison Test. Data
exhibiting a non-Gaussian distribution were analyzed with either
the Mann Whitney statistical test (2 groups) or the Kruskal-Wallis
with Dunn’s multiple comparison post-test (3 or more groups). For
analysis, results were regarded as significant if p values were less
than 0.05.
Supporting Information
Figure S1 Analysis of the myoferlin gene expression in
breast cancer cells. Graphical representation (mean 6 s.d.) of
expression data from two microarray probe sets for myoferlin
reported in the study by Neve and colleagues [34], showing a
higher expression (Kruskal-Wallis test/Dunn’s multiple compari-
son analysis) in the Basal B cells compared with the luminal cells.
(TIF)
Figure S2 Graphical representation from ArrayExpress
gene expression atlas (accession # E-TABM-276) of
MYOF mRNA expression level in breast tissue samples
from healthy patients and patients with invasive ductal
carcinoma.
(TIF)
Figure S3 Myoferlin lentiviral constructs. Target and
sequence information of lentiviral constructs used to generate
myoferlin-deficient cell lines. Bold letters indicate coding sequence.
(TIF)
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pletion in MDA-MB-231 cells. Growth curves (A) and cell
cycle analysis (B) of wild type (WT), lentiviral control (LTV-ctrl)
and myoferlin knockdown (MYOF-KD) MDA-MB-231 cells.
Statistical analysis on the proliferation curves (n $4, mean 6
s.d.) were done using linear regression on the log transformation of
the OD readings (p=0.43), showing an insignificance difference
among the proliferation rate of the cells. The cell cycle analysis (n
$4, mean 6 s.d.) also showed an insignificant difference in cell
proliferation (Gaussian approximation P value of 0.96, Kruskal-
Wallis/Dunn’s multiple comparison post-test).
(TIF)
Figure S5 Myoferlin depletion in MDA-MB-231 cells
alters the secretion of matrix metalloproteinases
(MMPs) and tissue inhibitors of MMPs (TIMPs). Anti-
body membrane-based array detecting various MMPs and TIMPs
was used to screen whether myoferlin depletion changes the
secretion of MMPs and TIMPs. 231
LTV-ctrl and 231
MYOF-KD cells
were serum starved for 24 h, and culture supernatants collected
and analyzed for extracellular matrix proteins. The intensity of the
quantified signals was normalized to 231
LTV-ctrl cells, and results
are expressed as fold changes.
(TIF)
Figure S6 MMP1 mRNA expression attenuated by
myoferlin depletion in MDA-MB-231 cells. Relative levels
of MMP1 mRNA in lentiviral-control (LTV-ctrl) and myoferlin
depleted (MYOF-KD) MDA-MB-231 cells. Levels of 18 S
expression were used to normalize the samples. Graph represents
fold change normalized to MMP1 levels in 231
LTV-ctrl cells (n=3,
mean 6 s.d.), showing a significant depletion of MMP1 mRNA in
231
MYOF-KD cells (unpaired t-test, p=0.003).
(TIF)
Figure S7 Myoferlin depletion in MDA-MB-231 cells by
separate shRNA constructs attenuates MMP1 produc-
tion. Immunoblotting (A) and ELISA (B) evaluation of secreted
MMP1 in 24 h serum starved supernatant of myoferlin depleted
MDA-MB-231 cells (constructs #10628 and #320398). Three
replicate samples of construct #320398 were ran (A–C). ELISA
results (n=3, mean 6 s.d.) show significant depletion of secreted
MMP1 in both myoferlin depleted MDA-MB-231 cells (one way
ANOVA/Tukey’s Multiple Comparison Test, p,0.01) when
compared with the lentiviral control cells.
(TIF)
Table S1 Reported is an alphabetical listing of genes
with Cp values less than 30 cycles for at least one of the
samples and with fold changes of $ 62-fold. Fold change
for genes up-regulated in MYOF-deficient MDA-MB-231 cells are
in bold, while the down-regulated genes are in italics.
(DOCX)
Table S2 Reported are fold changes at the mRNA level,
along with each MMP’s known ECM substrates [54].
MMPs with Cp values less than 30 cycles for at least one of the
samples are formatted in bold (MMP1, MMP10, MMP11, and
MMP14). Fold change for genes down-regulated in MYOF-
deficient MDA-MB-231 cells are in italics.
(DOCX)
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